Nangibotide and Monoclonal Antibodies

A novel approach to target inflammatory diseases

Restore a balanced inflammatory response

Using its proprietary technology platform, Inotrem is leveraging its extensive knowledge of the TREM-1 pathway biology to develop new therapeutic solutions in the field of immunotherapy around two categories of drug development programs: one centered on nangibotide, the other on monoclonal antibodies.


Nangibotide is Inotrem’s lead compound. It is a synthetic peptide and first-in-class TREM-1 inhibitor. Nangibotide blocks the TREM-1-mediated immune dysregulations in sterile or infectious acute inflammatory syndromes. Nangibotide restores a balanced inflammatory response and improves outcomes, particularly in those patients with high levels of TREM-1 pathway activation.

Monoclonal Antibodies

Over the last few years TREM-1 has been more frequently reported as being associated with chronic inflammatory diseases, fibrotic processes and more recently immuno-oncology. Based on Inotrem’s deep knowledge of the molecular mechanisms leading to the TREM-1 receptor activation, the research team launched a broad monoclonal antibody program in late 2018. A first program led to the advancement of an antagonist antibody to reach the development stage.